HuGE Navigator|HuGE Literature Finder|PHGKB

HuGE Literature Finder

Records 1-2

Query Trace: Leukopenia and BRCA1[original query]

Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 Sep . Westin Shannon N, Labrie Marilyne, Litton Jennifer K, Blucher Aurora, Fang Yong, Vellano Christopher P, Marszalek Joseph R, Feng Ningping, Ma Xiaoyan, Creason Allison, Fellman Bryan, Yuan Ying, Lee Sanghoon, Kim TaeBeom, Liu Jinsong, Chelariu-Raicu Anca, Chen Tsun Hsuan, Kabil Nashwa, Soliman Pamela T, Frumovitz Michael, Schmeler Kathleen M, Jazaeri Amir, Lu Karen H, Murthy Rashmi, Meyer Larissa, Sun Charlotte, Sood Anil K, Coleman Robert L, Mills Gordon Similar articles in PubMed
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth Similar articles in PubMed